Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Aardvark Therapeutics faces a securities class action filed in the Southern District of California covering purchases from Feb. 13, 2025 to May 14, 2026. The complaint alleges Defendants failed to disclose that ARD-101 was less safe than claimed and that clinical/regulatory/commercial prospects were overstated, with alleged partial disclosure beginning Feb. 27, 2026 when the company paused its Phase 3 HERO trial. After that announcement, Aardvark shares fell $7.02 per share (-56.2%) to close at $5.47 on March 2, 2026; the lead-plaintiff deadline is set for Oct. 13, 2026.

Analysis

This is a balance-sheet and financing problem disguised as a litigation headline. For a clinical-stage name, the market rarely prices the lawsuit itself; it prices the probability that the company will need to raise money into a damaged narrative, which means tighter terms, lower valuation, and a higher chance of an equity overhang before any operational recovery. The immediate loser is AARD, but the second-order loser is any small-cap biotech with a single-asset story and no near-term derisking event, because investors will demand a wider safety discount across the cohort.

The key catalyst path is not the court schedule; it is whether management can reframe the program with clean safety data over the next 1-3 months. If the company cannot produce a credible dose/exposure explanation quickly, the stock can remain structurally impaired for 6-18 months because capital markets will assume a lower probability of successful restart or partnership. That also spills into sector behavior: XBI can underperform on the margin when retail and crossover buyers see another example of “headline-to-zero” biology risk, even if the index-level effect is modest.

Contrarian view: the market may already be treating AARD as a broken-story name, so the incremental downside from the lawsuit could be limited unless there is new adverse disclosure, an equity raise, or a second safety signal. The bigger risk is upside traps—any bounce on procedural news may be faded if it does not come with verifiable clinical remediation. What would falsify the bearish thesis is a rapid protocol restart, clean safety readout at lower exposure, or a strategic deal that validates the asset despite the litigation backdrop.

Key Decisions for Investors

• No fresh long in AARD here; treat rallies on legal-process headlines as sellable unless the company restores trial momentum with hard safety data. Time horizon: 1-3 months; falsifier: credible restart of HERO without a new safety caveat.
• If borrow/liquidity are workable, short AARD into strength versus a biotech basket hedge (XBI) rather than outright naked shorting. This isolates company-specific financing risk while reducing factor noise; best risk/reward is after any relief rally, not on the initial gap.
• Use XBI as the cleaner expression for a cautious sector view only if the next 2-4 weeks bring more small-cap biotech safety or financing headlines. The trade works better as a tactical hedge than a structural short because the sector’s beta can reverse quickly on macro risk-on.
• Watch for any follow-on offering or shelf registration from AARD over the next 1-3 months; that would be the real bearish catalyst. If capital is raised at a heavy discount, the trade shifts from event-driven to a multi-quarter dilution story.